United Therapeutics Chairperson & CEO Martine Rothblatt Executes 10b5-1 Option Exercise and Sale

Executive Summary

On September 10, 2026, Dr. Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp ($UTHR), executed an exercise of 9,500 stock options at an exercise price of $117.76 per share and sold all 9,500 underlying common shares at weighted-average prices ranging from $498.44 to $508.80. The aggregate sale generated approximately $4.77 million in gross proceeds.

Transaction Details

• Option Exercise: Exercised 9,500 options expiring March 15, 2027, at $117.76 per share (acquisition cost: ~$1.12M).
• Open Market Sales: Sold 9,500 shares across multiple tranches at a volume-weighted average price of ~$502.35 per share.
• Plan Details: Conducted under a pre-established Rule 10b5-1 trading plan adopted on November 7, 2025.
• Remaining Holdings: Following the transactions, the primary family trust retains 324,443 shares of common stock and 461,410 derivative options, in addition to significant direct holdings (40,513 shares) and other indirect family trust holdings (~303,772 shares).

Market & Governance Context

Because these transactions were executed pursuant to an established Rule 10b5-1 trading plan and represent standard programmatic option exercises ahead of expiration, the market signaling impact is categorized as Low.